Interview With Lauren Taus

Is MindMed (MMED / MMEDF) the next Tesla (TSLA)? It could be. In this video we give the bull case scenario for MindMed, and give a general company overview.

MindMed (MMED) is our favorite psychedelic stock by far, with trials using LSD to treat anxiety and ADHD, as well as their proprietary 18-MC compound to treat addiction.

Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor

Music: www.bensound.com
► Music Credit: LAKEY INSPIRED
Track Name: “Blue Boi”
Music By: LAKEY INSPIRED @ https://soundcloud.com/lakeyinspired

Original upload HERE – https://www.youtube.com/watch?v=wAukv…
Official “LAKEY INSPIRED” YouTube Channel HERE – https://www.youtube.com/channel/UCOmy…
License for commercial use: Creative Commons Attribution 3.0 Unported “Share Alike” (CC BY-SA 3.0) License.
Full License HERE – https://creativecommons.org/licenses/…

Music promoted by NCM https://goo.gl/fh3rEJ

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

Links from studies and websites :
https://www.cdc.gov/nchs/pressroom/podcasts/20190911/20190911.htm?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y#:~:text=Anestimated69029peopledied,wereduetoheroin

https://www.hhs.gov/opioids/about-the-epidemic/index.html?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA

https://www.camh.ca/en/health-info/mental-illness-and-addiction-index/opioid-addiction?fbclid=IwAR31PQiu49359xjhzD4sTgcicRQLGh-l95y2DuFihHPdql87eHTDnYsTELw

https://preprod.drugfree.org/article/relapse-overdose/?fbclid=IwAR1YSZEIUDCiYDeBIYCk1WhEA_NJCrjyyz56zteyrbGKhDYQtsu2X1fDVOM

https://www.drugabuse.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery?fbclid=IwAR2_c4gVhURANeU5pCc0k97Ba4ML-kYZIGOZvGfqpHmo8o4jdxZp0SEHyQQ

https://maps.org/research-archive/presentations/Brown_GITA_Vancouver_Oct2012_iboga_comm_rev.pdf

https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218?fbclid=IwAR0OBK0eFJ64-v7gu1yE1TnyUIK1XhSDJvd_XLxhZaRtC4bWF8MfD0ine3M

https://www.healio.com/news/primary-care/20191205/ibogaine-treatment-for-opioid-use-disorder-what-you-need-to-know?fbclid=IwAR39o1sonUGLHsMGwH3pzbm3aAkU98P15CFNYaQX0r3VNQtJdSy3pazvRJM#

https://mindmed.co/psychedelic-inspired/?fbclid=IwAR1EK84fYX4WrObq45LkQfkZiW3ZtUYNsVZ4Y9q_wMHqas7y8IwoJmFyTBs#scroll_section-1

https://www.globenewswire.com/news-release/2020/02/20/1988216/0/en/Drug-Addiction-Treatment-Market-To-Reach-USD-31-17-Billion-By-2027-Reports-And-Data.html?fbclid=IwAR2ZeDBuW69x1DkczkxVRmadUBTpwu1Dilur64LkqBISH1Dqu8FC3EgFzmU

https://adaa.org/about-adaa/press-room/facts-statistics?fbclid=IwAR2YlG6rTd0jdUP3XIkm0t-_-QRYDyWDlVGh_sF6CZkayVEyGUZZpGcplwE#:~:text=Anxietydisordersarethemost,ofthosesufferingreceivetreatment

https://adaa.org/finding-help/treatment/medication?fbclid=IwAR10tRsqwdRMx-PqpKA9yx5BPGvNcVJRugkw3L6tq7DrDIO4gVdNwb6BGJ4

https://www.newswire.ca/news-releases/mindmed-receives-approval-of-protocol-design-to-evaluate-microdoses-of-lsd-for-adult-adhd-in-phase-2a-clinical-trial-from-swiss-and-dutch-health-authorities-897700369.html?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://maps.org/research-archive/lsd/Gasser-2014-JMND-4March14.pdf

https://www.smartpatients.com/trials/NCT03153579?fbclid=IwAR0df0UXoVhfWf03RQNkP5OMInM5Nyxz6j68V5GXr5lv0lDUuRL_R-UL4ZA

https://www.marketwatch.com/press-release/global-anxiety-disorders-and-depression-treatment-market-2020-research-report-with-consumption-revenue-opportunities-market-share-and-growth-rate-covid-19-impact-and-forecast-to-2026-absolute-reports-2020-11-06?fbclid=IwAR1jEtR6h9mTPla8OzW5RiIW2ecf_HnrT7of42bU4mO5dsfpxxuCAFv-7bE

https://www.additudemag.com/statistics-of-adhd/?fbclid=IwAR1mQaSVujUayYXwzCQRryiCZzM4gckjKAbg5O9H5BwCJIUbrXypOlgU4qM#:~:text=About6.1millionchildrenin,ControlandPrevention(CDC)

https://www.additudemag.com/adhd-medication-for-adults-and-children/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://www.floridarehab.com/drugs/meth/related/meth-vs-adderall/?fbclid=IwAR0WbOJtUIMcW4sPsQ7TUR-ulrPC9rwa1b2_KxHw_lFJBk_ygesCtsQJqDs

https://www.drugwatch.com/adderall/side-effects/?fbclid=IwAR3_UBSk2yv4lwOld0su1YpnJHsjPA4x5XK-X2pO5LMz1AeXiojkswcDV8Y

https://drug-dev.com/adhd-treatment-market-value-to-reach-9-9-billion/?fbclid=IwAR0jnNn2wDJocJEkfVGMtC1idTsBdupLZw-VQ0ddJskemRH0B8d50ykq0ng

https://mindmed.co/team/

#MindMed #MMED #Mindmedstock #Tesla #TSLA #PsychedelicStocks #ThePsychedelicInvestor

Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w

What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.

This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.

This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Check out our website: thepsychedelicinvestor.com

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

#MindMed #MNMD #PsychedelicStocks

MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.

Also, there were 0 cases of serious adverse side effects in the MDMA group.

So which companies will be the largest benefactors of these results?

Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently

2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.

3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.

4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.

5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.

Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

Clinical trials :

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #NUMIStock

Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy

When it comes to treating mental health conditions with psychedelic therapy, one of the most promising compounds is DMT, the main ingredient in the brew ayahuasca. While DMT may have many potential advantages over other similar compounds such as psilocybin, for example, its short duration of effect, the hallucination can be very intense.

It is an open question whether the mental health benefits we see from psychedelic therapy are due to the experience one undergoes when having a hallucination, or whether it comes strictly from the drug’s effects on the brain. If it is the latter, then hypothetically speaking, we could create a version of DMT that does not cause a hallucination.

Enter Psilera Biosciences.

Psilera is a psychedelic medicines company working to create next-generation psychedelics for use in therapeutic settings. Specifically, they aim to create non-psychedelic versions of classical psychedelics such as psilocybin, LSD and DMT.

PSIL-002 is Psilera’s version of non-hallucinogenic DMT. They recently completed a pre-clinical trial in mice that showed that their version of DMT was safe and non-psychedelic. Now they have to show that their version of DMT can treat depression and addiction, starting with alcoholism.

If Psilera’s DMT can treat these mental health conditions equally as well as regular DMT, but without the intense hallucination, then PSIL-002 would probably be the better compound.

It is exciting to see Psilera’s scientists working on answering the following questions:

Can DMT treat depression?
Can psychedelics help with depression?
Can psychedelics help with Mental Health?

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Video editing: @themyaholy @Psy_holy

#DMT #DEPRESSION #PSYCHEDELICTHERAPY